Cost of the Personal | GenomeWeb

Cost of the Personal

While genome sequencing may enable more personalized medicine, an article in Vancouver Sun examines how it may also lead to more expensive drugs. Because therapeutics targeted against certain genetic mutations may only then be effective in a sliver of the population, Randy Shore writes in the Sun that such 'orphan drugs' could command prices ranging between $100,000 and $1 million a year for each patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.